Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tanimilast add-on to maintenance triple therapy in COPD
NL-OMON59357Phase 3Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of tanimilast in chronic obstructive pulmonary disease (COPD) and chronic bronchitis (CB), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoint: Annual rate of moderate and severe exacerbations over 52 weeks. Started Oct 2021; status: completed.
02
Drugs
tanimilast
03
Conditions
chronic obstructive pulmonary disease (COPD)chronic bronchitis (CB)
Beyond the preview
Go deeper on NL-OMON59357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59357.